BioNTech Past Earnings Performance
Past criteria checks 0/6
BioNTech has been growing earnings at an average annual rate of 11.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 17.2% per year.
Key information
11.5%
Earnings growth rate
11.6%
EPS growth rate
| Biotechs Industry Growth | 18.9% |
| Revenue growth rate | 17.2% |
| Return on equity | -2.4% |
| Net Margin | -15.4% |
| Next Earnings Update | 05 May 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BioNTech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,040 | -467 | 609 | 2,220 |
| 30 Jun 24 | 2,691 | -504 | 612 | 2,168 |
| 31 Mar 24 | 2,730 | 113 | 566 | 1,957 |
| 31 Dec 23 | 3,819 | 930 | 558 | 1,783 |
| 30 Sep 23 | 6,618 | 2,751 | 550 | 1,715 |
| 30 Jun 23 | 9,184 | 4,375 | 550 | 1,559 |
| 31 Mar 23 | 12,213 | 6,238 | 560 | 1,585 |
| 31 Dec 22 | 17,311 | 9,434 | 541 | 1,537 |
| 30 Sep 22 | 18,565 | 10,322 | 556 | 1,299 |
| 30 Jun 22 | 21,191 | 11,748 | 480 | 1,217 |
| 31 Mar 22 | 23,303 | 12,863 | 394 | 1,019 |
| 31 Dec 21 | 18,977 | 10,293 | 327 | 949 |
| 30 Sep 21 | 13,790 | 7,493 | 229 | 935 |
| 30 Jun 21 | 7,770 | 4,072 | 178 | 902 |
| 31 Mar 21 | 2,503 | 1,197 | 139 | 796 |
| 31 Dec 20 | 482 | 15 | 109 | 645 |
| 30 Sep 20 | 165 | -410 | 79 | 453 |
| 30 Jun 20 | 126 | -230 | 63 | 275 |
| 31 Mar 20 | 110 | -192 | 57 | 232 |
| 31 Dec 19 | 109 | -179 | 49 | 227 |
| 30 Sep 19 | 144 | -122 | 53 | 208 |
| 30 Jun 19 | 136 | -116 | 48 | 191 |
| 31 Mar 19 | 132 | -77 | 38 | 168 |
| 31 Dec 18 | 128 | -48 | 32 | 141 |
| 31 Dec 17 | 62 | -86 | 34 | 82 |
Quality Earnings: 22UA is currently unprofitable.
Growing Profit Margin: 22UA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 22UA is unprofitable, but has reduced losses over the past 5 years at a rate of 11.5% per year.
Accelerating Growth: Unable to compare 22UA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 22UA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 22UA has a negative Return on Equity (-2.44%), as it is currently unprofitable.